ProKidney

PROKPhase 3

ProKidney is focused on transforming the treatment of chronic kidney disease through its proprietary renal autologous cell therapy, rilparencel. The company is advancing this therapy in a pivotal Phase 3 program (PROACT 1) for patients with advanced CKD and type 2 diabetes, following promising Phase 2 results. With over 35 million U.S. adults affected by CKD and approximately 135,000 progressing to dialysis annually, ProKidney aims to provide a therapeutic option to delay disease progression and the need for renal replacement therapy.

Market Cap

$273.2M

Focus

Cell & Gene Therapy

PROK · Stock Price

USD 1.937.97 (-80.51%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Renal Autologous Cell Therapy (RACT) platform for harvesting, processing, and re-implanting a patient's own renal cells to promote tissue repair and regeneration in the kidney.

Pipeline Snapshot

10 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Renal Autologous Cell Therapy (REACT/ rilparencel)	Type 2 Diabetes Mellitus	Phase 3
Renal Autologous Cell Therapy (REACT)	Type 2 Diabetes Mellitus	Phase 3
Renal Autologous Cell Therapy (REACT)	Type 2 Diabetes Mellitus	Phase 2
Renal Autologous Cell Therapy (REACT)	Type 2 Diabetes Mellitus	Phase 2
Renal Autologous Cell Therapy (REACT)	Chronic Kidney Diseases	Phase 2

Funding History

Total raised: $325M

PIPE$250MUndisclosedJan 1, 2022

Series D$75MUndisclosedJan 1, 2021

Opportunities

The primary opportunity is the vast, underserved population of over 35 million U.S.

adults with CKD, particularly the ~135,000 who progress to dialysis annually.

Successful Phase 3 data could establish rilparencel as a first-in-class regenerative therapy, commanding a premium price and capturing significant market share in a multi-billion dollar indication.

The autologous platform could also be explored for other renal indications.

Risk Factors

Key risks include clinical trial failure in Phase 3, regulatory challenges for a novel cell therapy, complex and costly autologous manufacturing/logistics, future capital needs leading to dilution, and commercial adoption hurdles against established pharmaceutical therapies.

Competitive Landscape

Competitors include large pharma with SGLT2 and GLP-1 drugs (AstraZeneca, Eli Lilly, Novo Nordisk) and other biotechs targeting kidney disease (Chinook/Novartis, Travere). ProKidney's main differentiation is its direct, autologous, tissue-regenerative approach, a unique mechanism in late-stage development for CKD.

Publications

Patents

Pipeline